Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. - Wikidata - wikimedia - TriplyDB

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

http://www.wikidata.org/entity/Q38874291

about

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a review Checkpoint inhibitors in hematological malignancies Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing Novel Immunotherapies for Multiple Myeloma.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Allogeneic stem cell transplantation for multiple myeloma: is there a future?Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.How is patient care for multiple myeloma advancing?Programming the immune checkpoint to treat hematologic malignancies.Vision Statement for Multiple Myeloma: Future Directions.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Targeting Immune Checkpoints in Hematologic Malignancies.Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.Is immunotherapy here to stay in multiple myeloma?Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression New monoclonal antibodies on the horizon in multiple myeloma Targeting the programmed death-1 pathway in lymphoid neoplasms.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.Emerging drugs and combinations to treat multiple myeloma.The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Promising therapies in multiple myeloma.Progress and Paradigms in Multiple Myeloma.

P2860

Q33638083-04E7829D-EF87-4592-9185-DE214AC231E5 Q33645590-E53A929A-3E70-4FF5-BD34-CC827AD632FE Q33651495-051EA7DC-8C8C-4B3B-817C-53B0E040D147 Q33909086-8D6B97C3-9C61-4E92-B124-20E68B4EB1EA Q36685551-8F71ADF4-F3AF-4CDD-8AF8-B1769FF49682 Q37035836-A302A155-10A8-4C86-B71E-5DF44718D821 Q37390723-68F23567-C209-401B-A7A5-B82451ED172E Q37437357-2AEDAE36-95C3-4C62-8FAD-5B8CE31535AD Q37517482-1F7BF34C-21A9-4501-A472-F66F8104659D Q37641801-4C6DA228-9739-4B54-AA2C-301606EA037F Q37710498-4ADE07BF-B345-4EC4-9715-1D19864A983D Q38640444-B582542D-DC1F-4A62-9322-09684D19C057 Q38672091-27013853-78BB-465D-8665-4B2916700AD6 Q38685796-1F215B1F-5A69-486E-90C4-EE1FE802C87D Q38720340-7652C84C-6413-4F75-83D9-86BDABDB5032 Q38765760-873BCD73-2AB7-475C-B956-50CA6A12873E Q38786149-50AC6F5A-F665-428E-9447-D317B7EAC7A3 Q38806070-0BE14DAE-8B70-4763-9A8A-14F9DC1DEEA1 Q38815409-ED8F3F76-7BC3-4960-A611-17431ED8AAC7 Q38843235-E4A4A6FB-75A7-46F3-AC79-7D07226CFD73 Q38847251-8B56920D-02B6-4182-A0C1-2B0B88ABE123 Q38932298-B1E90028-2BDD-4CCB-B938-C25A3781415D Q38963420-86763DBA-2F61-413E-AEE3-E071ABA7FBAF Q38996881-B46E9E43-56A7-49CD-ABEB-6BEB9900518C Q39043404-E460E65E-CAA8-4C2F-AE38-DD9F63E19EC3 Q39055861-968D94D4-42F4-4AD4-8362-C35DDFAE72F8 Q39072004-91F5C427-E033-4756-A9C5-7DAB706C653D Q39084427-BFB9C8A6-6389-4376-966D-6EF961652BC1 Q39136762-947961B6-7DA1-4506-A906-5D1DD945E13D Q39137696-4911ADDB-1FC8-44E8-ADE8-BA8DA714BDEB Q39153358-DA33D941-8BE9-4D7A-826D-9FCD63AEC4F3 Q39420466-93E185E7-33F9-4149-A41F-A769294B8F6E Q39832619-8B5E06EF-4649-4ABF-93CF-3374E110915B Q39901834-83B4C035-3A0F-4B7E-B2BC-5099A87B5090 Q40382947-8EA2E88A-D6D1-4686-86DD-3835AB16F1C0 Q41694198-8168F269-A3B6-4E1B-949D-1756D99693E4 Q41708947-2B950864-6996-457A-817B-FB688E540FC0 Q42042886-BBF03ED6-070A-48C3-904F-12A037E34B46 Q42581682-004D8F3A-304F-4AF0-BF07-312C70E5E796 Q44694137-CDA54670-A6A7-422B-8239-26D672EE91AB

P2860

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

http://www.wikidata.org/entity/Q38874291

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Lenalidomide Enhances Immune C ...... Response in Multiple Myeloma.

@en

type

label

Lenalidomide Enhances Immune C ...... Response in Multiple Myeloma.

@en

prefLabel

Lenalidomide Enhances Immune C ...... Response in Multiple Myeloma.

@en

P1433

Q38874291-BD8D4C8C-A427-471F-9298-F1D6B3EDB62E

P1476

Q38874291-5C3779F9-B0DE-4EFF-9A1B-B73B66B4C295

P2093

Q38874291-0E72228E-B53D-4813-851E-741873DA94DD

Q38874291-11DBBF09-9EC5-43F6-AFD8-29E99CA08D4B

Q38874291-22971E8C-107B-4B91-ADE9-15AF7BA78C4A

Q38874291-4627E95A-44AD-4E58-AA86-F7D61E566AEF

Q38874291-5096410C-62AA-4100-8BB3-E812ED8E42D0

Q38874291-636F0AF7-AFE2-4550-8FE9-80A3AFA63F0E

Q38874291-6EE91D6F-7AEA-41C3-9EB0-CD39ABCA242A

Q38874291-748F105F-AAF5-4B3D-80C1-33B3FCE75A3A

Q38874291-9EAA6FBC-E2F2-4179-BD87-FA0D36B35B5B

Q38874291-A6FC2901-AE3D-40CD-9C06-053FA2CD7B54

P2860

Q38874291-010BC392-558D-4209-A4AC-D69F6B3FE8BE

Q38874291-1665FAC5-B5F2-423C-836E-31AD23C52E42

Q38874291-2B2B7BE7-3593-47F6-8FC4-9638139D0989

Q38874291-36E48226-511B-42BE-A3E1-D5B9BF042FE4

Q38874291-38E528BE-590D-4F96-A401-5DD71AABB477

Q38874291-392E3D92-0CC0-4EF4-AABF-1D23F72269EB

Q38874291-39E0FC66-8337-441F-935A-4916322F613E

Q38874291-45BFDB77-AD6F-4311-AE87-4B92897C839E

Q38874291-477E613B-0AA4-490F-BD4E-076BE4145238

Q38874291-5026CF77-71AA-4F57-9DC1-1433A99E5BD0

P304

Q38874291-ABDCED2C-B74B-41AF-87B9-A57E5FC8118F

P31

Q38874291-3F1CD440-E0B0-4987-B82F-241C44830244

P356

Q38874291-F71F176B-A3F2-428D-AEC6-8854F33A82A2

P407

Q38874291-BCD018E5-CD83-4F6F-ABF4-DC57E18A435D

P433

Q38874291-F2866672-4570-4D92-9CAA-47449833635B

P478

Q38874291-F4E982FA-676D-41A0-9C95-04B78DE908F9

P50

Q38874291-2377BEC5-F202-4580-B254-A56D8D1BB45E

Q38874291-A382A5DC-C32E-40C9-A356-652EA9199BC7

Q38874291-C8ECE377-7BE1-4855-B448-2151E2587715

Q38874291-DD8E90BB-0016-4181-A20F-3AF030FDBEB6

P577

Q38874291-2DAB673A-E3E4-45B7-9AA7-EFDAF58FCF7D

P698

Q38874291-F68B63DC-AEE7-4222-B966-0D6636BAE490

P932

Q38874291-0D664833-34CA-44F3-8DCA-4A68AA32DC9C

P356

1078-0432.CCR-15-0200

P1433

Clinical Cancer Research

P1476

Lenalidomide Enhances Immune C ...... Response in Multiple Myeloma.

@en

P2093

Ahaana Singh

http://www.w3.org/2001/XMLSchema#string

David M Dorfman

http://www.w3.org/2001/XMLSchema#string

Giada Bianchi

http://www.w3.org/2001/XMLSchema#string

Güllü Görgün

http://www.w3.org/2001/XMLSchema#string

Hiroto Ohguchi

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Julie E Anderson

http://www.w3.org/2001/XMLSchema#string

Kristen B Cowens

http://www.w3.org/2001/XMLSchema#string

Mehmet K Samur

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

PD-1 and its ligands in tolerance and immunity

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

P304

4607-4618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-15-0200

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Hervé Avet-Loiseau

Florence Magrangeas

Kenneth C Anderson

Paul G Richardson

P577

2015-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25979485

http://www.w3.org/2001/XMLSchema#string

P932

4609232

http://www.w3.org/2001/XMLSchema#string